Literature DB >> 8235859

Neutral proteinases in human intervertebral disc. Role in degeneration and probable origin.

K Fujita1, T Nakagawa, K Hirabayashi, Y Nagai.   

Abstract

Neutral proteinases were partially purified from human intervertebral disc by extraction with guanidine hydrochloride followed by Sephadex G-75 column chromatography. They showed gelatinolytic and elastolytic activities at neutral pH. The apparent molecular weights of these enzymes were 70 KD and 25 KD, the former being the complexed form of the latter. The sensitivity to various synthetic inhibitors indicated these enzymes to be serine elastases. Furthermore, they were considered to be leukocyte elastases because anti-leukocyte elastase antibody inhibited the proteinase activity of these enzymes. Proteinase activity was not detected in normal discs, except for some slight activity in the end-plate. In contrast, the degenerated discs showed high activity, especially in the nucleus pulposus and end-plate. Similar high levels of proteinase activity were found in the vertebral body adjacent to normal as well as degenerated discs. These findings suggest that leukocyte elastase, which is normally present in the vertebral body, flows into and degrades the matrix of the intervertebral disc under pathologic conditions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8235859     DOI: 10.1097/00007632-199310000-00009

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  10 in total

Review 1.  Emerging technologies for molecular therapy for intervertebral disk degeneration.

Authors:  Won C Bae; Koichi Masuda
Journal:  Orthop Clin North Am       Date:  2011-10       Impact factor: 2.472

Review 2.  Molecular therapy of the intervertebral disc.

Authors:  S Tim Yoon; Nilpesh M Patel
Journal:  Eur Spine J       Date:  2006-07-12       Impact factor: 3.134

Review 3.  Prevention of disc degeneration with growth factors.

Authors:  Koichi Masuda; Howard S An
Journal:  Eur Spine J       Date:  2006-07-25       Impact factor: 3.134

4.  Is there any relationship between proinflammatory mediator levels in disc material and myelopathy with cervical disc herniation and spondylosis? A non-randomized, prospective clinical study.

Authors:  Mehmet Nusret Demircan; Alparslan Asir; Ahmet Cetinkal; Nursal Gedik; Ahmet Murat Kutlay; Ahmet Colak; Sedat Kurtar; Hakan Simsek
Journal:  Eur Spine J       Date:  2007-05-03       Impact factor: 3.134

5.  Anulus fibrosus tension inhibits degenerative structural changes in lamellar collagen.

Authors:  Jeffrey C Lotz; Tamer Hadi; Clayton Bratton; Karen M Reiser; Adam H Hsieh
Journal:  Eur Spine J       Date:  2008-07-31       Impact factor: 3.134

6.  Intervertebral disc degeneration: biological and biomechanical factors.

Authors:  Howard S An; Koichi Masuda; Nozomu Inoue
Journal:  J Orthop Sci       Date:  2006-10       Impact factor: 1.601

7.  Elastase from polymorphonuclear leukocyte in articular cartilage and synovial fluids of patients with rheumatoid arthritis.

Authors:  S Momohara; S Kashiwazaki; K Inoue; S Saito; T Nakagawa
Journal:  Clin Rheumatol       Date:  1997-03       Impact factor: 2.980

8.  The presence and absence of lymphatic vessels in the adult human intervertebral disc: relation to disc pathology.

Authors:  Karolina Kliskey; Kelly Williams; J Yu; David Jackson; Jill Urban; Nick Athanasou
Journal:  Skeletal Radiol       Date:  2009-12       Impact factor: 2.199

9.  Mesenchymal stem cell for prevention and management of intervertebral disc degeneration.

Authors:  Umile Giuseppe Longo; Nicola Papapietro; Stefano Petrillo; Edoardo Franceschetti; Nicola Maffulli; Vincenzo Denaro
Journal:  Stem Cells Int       Date:  2012-03-04       Impact factor: 5.443

Review 10.  Growth factors and anticatabolic substances for prevention and management of intervertebral disc degeneration.

Authors:  Umile Giuseppe Longo; Stefano Petrillo; Edoardo Franceschetti; Nicola Maffulli; Vincenzo Denaro
Journal:  Stem Cells Int       Date:  2011-11-03       Impact factor: 5.443

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.